Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
AssigneeUniversity of Kentucky Research Foundation
InventorAnwar A. Hussain
Life of this patent
Estimating the term…
Abstract
The invention provides a novel method of administering narcotic antagonists, narcotic analgesics and related compounds, and novel dosage forms containing those compounds which are adapted for nasal administration. The nasal dosage forms disclosed include solutions, suspensions, gels and ointments. Especially preferred compounds which can be advantageously administered in accordance with the invention include naloxone, naltrexone, nalbuphine, levorphanol, buprenorphine, butorphanol, .DELTA..sup.9 -tetrahydrocannabinol (THC), cannabidiol (CBD) and levonantradol.
Claims51
A method for eliciting an analgesic or narcotic antagonist response in a warm-blooded animal, which comprises nasally administering to said animal:
- (a) to elicit an analgesic response, an analgesically effective amount of morphine, hydromorphone, metopon, oxymorphone, desomorphine, dihydromorphine, levorphanol, cyclazocine, phenazocine, levallorphan, 3-hydroxy-N-methylmorphinan, levophenacylmorphan, metazocine, norlevorphanol, phenomorphan, nalorphine, nalbuphine, buprenorphine, butorphanol or pentazocine, or a nontoxic pharmaceutically acceptable acid addition salt thereof;
- or
- (b) to elicit a narcotic antagonist response, a narcotic antagonist effective amount of naloxone, naltrexone, diprenorphine, nalmexone, cyprenorphine, levallorphan, alazocine, oxilorphan, cyclorphan, nalorphine, nalbuphine, buprenorphine, butorphanol, cyclazocine or pentazocine, or a nontoxic pharmaceutically acceptable acid addition salt thereof.
A pharmaceutically acceptable nasal dosage form for eliciting an analgesic response in a warm-blooded animal, which comprises (i) an analgesically effective amount of morphine, hydromorphone, metopon, oxymorphone, desomorphine, dihydromorphine, levorphanol, cyclazocine, phenazocine, 3-hydroxy-N-methylmorphinan, levophenacylmorphan, metazocine, norlevorphanol, phenomorphan, nalorphine, nalbuphine, buprenorphine, butorphanol, levallorphan or pentazocine, or a nontoxic pharmaceutically acceptable acid addition salt thereof, and (ii) a nontoxic pharmaceutically acceptable nasal carrier therefor, said nasal dosage form comprising a nasal ointment or a nasal gel.
A pharmaceutically acceptable nasal dosage form for eliciting a narcotic antagonist response in a warm-blooded animal, which comprises (i) a narcotic antagonist effective amount of naloxone, naltrexone, diprenorphine, nalmexone, cyprenorphine, levallorphan, alazocine, oxilorphan, cyclorphan, nalorphine, nalbuphine, buprenorphine, butorphanol, cyclazocine or pentazocine, or a nontoxic pharmaceutically acceptable acid addition salt thereof, and (ii) a nontoxic pharmaceutically acceptable nasal carrier therefor, said nasal dosage form comprising a nasal ointment or a nasal gel.
A pharmaceutically acceptable sustained release nasal dosage form for nasally delivering systemic therapeutic levels of drug to a warm-blooded animal which comprises (i) a systemically therapeutically effective amount of a long chain carboxylic acid salt of morphine, hydromorphone, metopon, oxymorphone, desomorphine, dihydromorphine, levorphanol, cyclazocine, phenazocine, 3-hydroxy-N-methylmorphinan, levophenacylmorphan, metazocine, norlevorphanol, phenomorphan, nalorphine, nalbuphine, buprenorphine, butorphanol, pentazocine, naloxone, naltrexone, diprenorphine, nalmexone, cyprenorphine, levallorphan, alazocine, oxilorphan or cyclorphan, and (ii) a nontoxic pharmaceutically acceptable nasal carrier therefor.
Dependencies are inferred from the claim text.